These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

483 related articles for article (PubMed ID: 17002161)

  • 1. [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].
    Båvenholm P; Attvall S; Nilsson PM
    Lakartidningen; 2006 Aug 30-Sep 5; 103(35):2462-6. PubMed ID: 17002161
    [No Abstract]   [Full Text] [Related]  

  • 2. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
    Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
    [No Abstract]   [Full Text] [Related]  

  • 3. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus.
    Betteridge J
    Am J Med; 2005 Dec; 118 Suppl 12A():10-5. PubMed ID: 16356802
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.
    Jones PH
    Am J Cardiol; 2007 Feb; 99(4A):133B-140B. PubMed ID: 17307065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is it time to stop treating dyslipidaemia with fibrates?
    Benatar JR; Stewart RA
    N Z Med J; 2007 Sep; 120(1261):U2706. PubMed ID: 17853928
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diabetic dyslipidemia: extending the target beyond LDL cholesterol.
    Nicholls SJ; Lundman P; Tardif JC
    Eur J Cardiovasc Prev Rehabil; 2010 May; 17 Suppl 1():S20-4. PubMed ID: 20489416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [On behalf and the extent of evidence].
    Ruiz J
    Rev Med Suisse; 2010 Jun; 6(252):1171-2. PubMed ID: 20614750
    [No Abstract]   [Full Text] [Related]  

  • 8. Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.
    Schima SM; Maciejewski SR; Hilleman DE; Williams MA; Mohiuddin SM
    Expert Opin Pharmacother; 2010 Apr; 11(5):731-8. PubMed ID: 20210682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FIELD study.
    Rees A
    Diabet Med; 2006 Jul; 23 Suppl 3():6-12. PubMed ID: 16805876
    [No Abstract]   [Full Text] [Related]  

  • 10. Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.
    Cardiovasc J Afr; 2008; 19(3):171-2. PubMed ID: 18568186
    [No Abstract]   [Full Text] [Related]  

  • 11. Management of dyslipidemia in diabetes.
    Solano MP; Goldberg RB
    Cardiol Rev; 2006; 14(3):125-35. PubMed ID: 16628021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    Jones PH
    Am J Cardiol; 2008 Dec; 102(12A):41L-47L. PubMed ID: 19084089
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing cardiovascular risk in diabetes: beyond glycemic and blood pressure control.
    Hobbs FD
    Int J Cardiol; 2006 Jun; 110(2):137-45. PubMed ID: 16289373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.
    Steinmetz A
    Diabetes Metab Res Rev; 2008; 24(4):286-93. PubMed ID: 18273835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Disorders of lipid metabolism in 3 patients with diabetes mellitus type 2].
    Wolffenbuttel BH; Huijberts MS
    Ned Tijdschr Geneeskd; 2001 Apr; 145(16):761-5. PubMed ID: 11346911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Favorable effects of decreasing lipids in patients with diabetes mellitus].
    Gouni-Berthold I; Krone W
    Dtsch Med Wochenschr; 2006 Dec; 131 Suppl 8():S252-4. PubMed ID: 17139581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [CARDS confirms usefulness of LDL lowering in type 2 diabetics].
    Bern VH
    Praxis (Bern 1994); 2004 Oct; 93(44):1 p following 1830. PubMed ID: 15559908
    [No Abstract]   [Full Text] [Related]  

  • 18. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):34L-40L. PubMed ID: 19084088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(2):118-9. PubMed ID: 20532440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug insight: the role of statins in combination with ezetimibe to lower LDL cholesterol.
    Gotto AM; Farmer JA
    Nat Clin Pract Cardiovasc Med; 2006 Dec; 3(12):664-72. PubMed ID: 17122799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.